Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wenyan Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1855-6245; OpenAlex author ID A5101735276. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 7 papers · 2017: 6 papers · 2018: 3 papers · 2019: 5 papers · 2020: 3 papers · 2021: 5 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 2 papers

Papers 39

  1. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  2. The ACSS2-PPARD-BCAT1 axis synchronously regulates branched-chain amino acid metabolism and development in pancreatic cancer. Co-author DOI 10.3724/abbs.2025111↗
  3. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective c… Co-author DOI 10.1186/s12957-023-03277-2↗
  4. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  5. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Last author DOI 10.3389/fonc.2022.822039↗
  6. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.11.023↗
  7. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.redox.2020.101807↗
  8. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Co-author DOI 10.1093/abbs/gmab074↗
  9. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  10. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Last author DOI 10.1186/s12935-021-02210-5↗
  11. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  12. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  13. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  14. ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. Co-author DOI 10.1097/mpa.0000000000001408↗
  15. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  16. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. First author DOI 10.1186/s12935-019-0767-4↗
  17. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  18. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Co-author PMID 31911852↗
  19. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  20. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  21. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Co-author DOI 10.7150/thno.26546↗
  22. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.12.014↗
  23. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
  24. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.2147/ott.s145708↗
  25. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  26. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Co-author DOI 10.3892/or.2017.5856↗
  27. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
  28. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  29. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2016.09.001↗
  30. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  31. Energy sources identify metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1093/abbs/gmw097↗
  32. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancr… Co-author DOI 10.1158/1078-0432.ccr-15-2380↗
  33. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer. Co-author DOI 10.2174/1566524016666160316154150↗
  34. Critical role of oncogenic KRAS in pancreatic cancer (Review). Co-author DOI 10.3892/mmr.2016.5196↗
  35. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.02.014↗
  36. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Co-author DOI 10.1038/cr.2015.30↗
  37. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Co-author DOI 10.1016/j.canlet.2014.02.013↗
  38. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Co-author DOI 10.1186/1476-4598-13-187↗
  39. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Co-author DOI 10.4161/cbt.13.4.18692↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shunrong Ji · 38 shared papers, 2012–2025 · strength 3.31
  2. Xianjun Yu · 38 shared papers, 2012–2025 · strength 3.29
  3. Yi Qin · 33 shared papers, 2014–2025 · strength 2.58
  4. Wensheng Liu · 19 shared papers, 2017–2024 · strength 2.03
  5. Qiangsheng Hu · 20 shared papers, 2016–2021 · strength 1.67
  6. Xiaowu Xu · 14 shared papers, 2019–2025 · strength 1.67
  7. Jin Xu · 23 shared papers, 2014–2025 · strength 1.45
  8. Qifeng Zhuo · 9 shared papers, 2020–2024 · strength 1.16
  9. Si Shi · 19 shared papers, 2014–2025 · strength 1.13
  10. Quanxing Ni · 20 shared papers, 2012–2019 · strength 1.12
  11. Zheng Zhang · 11 shared papers, 2018–2021 · strength 1.06
  12. Ye Zeng · 7 shared papers, 2020–2025 · strength 0.92
  13. Mengqi Liu · 8 shared papers, 2019–2024 · strength 0.90
  14. Qiqing Sun · 10 shared papers, 2018–2020 · strength 0.89
  15. Dingkong Liang · 14 shared papers, 2015–2018 · strength 0.77
  16. Chen Liang · 13 shared papers, 2016–2018 · strength 0.73
  17. Jinfeng Xiang · 10 shared papers, 2016–2019 · strength 0.63
  18. Xiaowu Xu · 4 shared papers, 2019–2025 · strength 0.60
  19. Chen Liu · 10 shared papers, 2014–2025 · strength 0.59
  20. Haidi Chen · 3 shared papers, 2021–2025 · strength 0.54
  21. Liang Liu · 10 shared papers, 2014–2017 · strength 0.46
  22. Ye Zeng · 4 shared papers, 2019–2021 · strength 0.43
  23. Chenjie Zhou · 2 shared papers, 2024–2025 · strength 0.42
  24. Bo Zhang · 5 shared papers, 2017–2019 · strength 0.37
  25. Kaizhou Jin · 4 shared papers, 2016–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.